These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 27270097

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging.
    Kelly J, Amor-Coarasa A, Nikolopoulou A, Kim D, Williams C, Ponnala S, Babich JW.
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
    Harada N, Kimura H, Onoe S, Watanabe H, Matsuoka D, Arimitsu K, Ono M, Saji H.
    J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
    [Abstract] [Full Text] [Related]

  • 6. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
    Lim J, Guan B, Nham K, Hao G, Sun X, Simanek EE.
    Biomolecules; 2019 Aug 28; 9(9):. PubMed ID: 31466360
    [Abstract] [Full Text] [Related]

  • 7. 18 F-labeled 1,2,3-triazole-linked Glu-urea-Lys-based PSMA ligands have good pharmacokinetic properties for positron emission tomography imaging of prostate cancer.
    Lee BS, Chu SY, Jung WJ, Jeong HJ, Lee K, Kim MH, Kim MH, Chi DY, Ahn H, Lee YJ, Lee KC, Lim SM.
    Prostate; 2020 Dec 28; 80(16):1383-1393. PubMed ID: 32960990
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile.
    Bouvet V, Wuest M, Bailey JJ, Bergman C, Janzen N, Valliant JF, Wuest F.
    Mol Imaging Biol; 2017 Dec 28; 19(6):923-932. PubMed ID: 28639122
    [Abstract] [Full Text] [Related]

  • 10. (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy.
    Kiess AP, Minn I, Vaidyanathan G, Hobbs RF, Josefsson A, Shen C, Brummet M, Chen Y, Choi J, Koumarianou E, Baidoo K, Brechbiel MW, Mease RC, Sgouros G, Zalutsky MR, Pomper MG.
    J Nucl Med; 2016 Oct 28; 57(10):1569-1575. PubMed ID: 27230930
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
    Benešová M, Schäfer M, Bauder-Wüst U, Afshar-Oromieh A, Kratochwil C, Mier W, Haberkorn U, Kopka K, Eder M.
    J Nucl Med; 2015 Jun 28; 56(6):914-20. PubMed ID: 25883127
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
    Hillier SM, Maresca KP, Lu G, Merkin RD, Marquis JC, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW.
    J Nucl Med; 2013 Aug 28; 54(8):1369-76. PubMed ID: 23733925
    [Abstract] [Full Text] [Related]

  • 17. 111In- and IRDye800CW-Labeled PLA-PEG Nanoparticle for Imaging Prostate-Specific Membrane Antigen-Expressing Tissues.
    Banerjee SR, Foss CA, Horhota A, Pullambhatla M, McDonnell K, Zale S, Pomper MG.
    Biomacromolecules; 2017 Jan 09; 18(1):201-209. PubMed ID: 28001364
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. In Vitro and In Vivo Characterization of an 18F-AlF-Labeled PSMA Ligand for Imaging of PSMA-Expressing Xenografts.
    Lütje S, Franssen GM, Herrmann K, Boerman OC, Rijpkema M, Gotthardt M, Heskamp S.
    J Nucl Med; 2019 Jul 09; 60(7):1017-1022. PubMed ID: 30655329
    [Abstract] [Full Text] [Related]

  • 20. Single Chelator-Minibody Theranostic Agents for 89Zr PET Imaging and 177Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer.
    Ho KV, Tatum DS, Watkinson L, Carmack T, Jia F, Mascioni A, Maitz CA, Magda D, Anderson CJ.
    J Nucl Med; 2024 Sep 03; 65(9):1435-1442. PubMed ID: 39142831
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.